- Harrow Health Inc HROW entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis AG NVS.
- This acquisition will further expand and diversify Harrow's portfolio of branded pharmaceutical products and its ability to serve the U.S. ophthalmic surgical and acute care markets.
- Assuming this transaction closes during Q1 of 2023, Harrow expects 2023 net revenues of $135-$143 million and adjusted EBITDA of $44-$50 million.
- Harrow will make a one-time payment of $130 million, with up to an additional $45 million payable in a milestone payment upon the commercial availability of TRIESENCE, which is expected in 2H of 2023.
- Novartis will retain all rights to the products outside of the U.S.
- Harrow commenced an underwritten registered public offering of $100 million aggregate principal amount of senior notes due 2027 to fund a portion of the purchase price payable for a previously announced acquisition.
- The company also priced an underwritten registered offering of 2.37 million shares at $10.52 for aggregate gross proceeds of $25 million.
- Price Action: HROW shares are up 6.31% at $11.80 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in